NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.
Wednesday, May 7, 2025
Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over (terminated appraisal)
National Institute for Health and Care Excellence (NICE). 06 May 2025.
